Biotech Values

[genisi]

Interestingly the lesson I take away from this is that if you are putting such drugs through the clinic it behooves you to predefine a set of subtypes and check. If you do this you are likely to find some stellar efficacies and some subgroups to stay away from.

In this paragraph you have summarized the essence of tailored targeted therapy. Since cancer types can be divided into subcategories and further by the molecular signals driving each one, plus we know there is heterogeneity not only between but also within tumors, clearly therapies need to be more precise. People in the industry understood that and Roche Diagnostics is an example of implementing this: Roche is already developing the vast majority of its new molecules with a companion diagnostic in order to defined population groups to a drug's MoA as early as possible, because of all the obvious advantages (better early stage detection, finding likely responders/non-responders, improve patient outcomes, shorting development process, finding the better combination, and even improve reimbursement).